Literature DB >> 32101479

The abscopal effect 67 years later: from a side story to center stage.

Sandra Demaria1,2,3, Silvia C Formenti1,2.   

Abstract

For over a century, ionising radiation has been used to treat cancer based on its cytotoxic effects on tumour cells. Technical progress has enabled more precise targeting of the tumour to reduce normal tissue toxicity while delivering higher radiation doses per fraction of treatment.In 1953, unexpected regression in lesions outside of the irradiated field were noted by an observant physician, RH Mole, who named such phenomenon "abscopal effect" from the Latin ab (position away from) and scopus (mark or target), in an article published in this journal. Clinical abscopal responses have been reported over the years but because of their very rare occurrence they could not be methodically studied, remaining akin to a curiosity. Nevertheless, their occurrence has ignited interest in studying the systemic effects of radiotherapy. Progress in dissecting the mechanisms that govern the function of the immune system in cancer has enabled to study the implication of immunity in the abscopal effect of radiation. It has become clear that ionising radiation activates canonical pathways of response to viral infections, and can stimulate antitumour immunity. These immune stimulatory effects of radiation have become clinically relevant in the current era of cancer immunotherapy, rendering abscopal responses in patients an attainable aim. Here, we will briefly review the parallel evolutions of two separate fields of medicine, radiation therapy and cancer immunology, and discuss their therapeutic partnership.

Entities:  

Mesh:

Year:  2020        PMID: 32101479      PMCID: PMC7217574          DOI: 10.1259/bjr.20200042

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  85 in total

1.  Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer.

Authors:  P K Chakravarty; A Alfieri; E K Thomas; V Beri; K E Tanaka; B Vikram; C Guha
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

2.  Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.

Authors:  A van Elsas; A A Hurwitz; J P Allison
Journal:  J Exp Med       Date:  1999-08-02       Impact factor: 14.307

Review 3.  Radiotherapy: Changing the Game in Immunotherapy.

Authors:  Sandra Demaria; C Norman Coleman; Silvia C Formenti
Journal:  Trends Cancer       Date:  2016-06

4.  A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab.

Authors:  Ravi A Chandra; Tyler J Wilhite; Tracy A Balboni; Brian M Alexander; Alexander Spektor; Patrick A Ott; Andrea K Ng; F Stephen Hodi; Jonathan D Schoenfeld
Journal:  Oncoimmunology       Date:  2015-05-28       Impact factor: 8.110

5.  In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.

Authors:  Anna R Kwilas; Renee N Donahue; Michael B Bernstein; James W Hodge
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

6.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.

Authors:  Mercedes B Fuertes; Aalok K Kacha; Justin Kline; Seng-Ryong Woo; David M Kranz; Kenneth M Murphy; Thomas F Gajewski
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307

7.  Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production.

Authors:  Hiroyasu Konno; Shota Yamauchi; Anders Berglund; Ryan M Putney; James J Mulé; Glen N Barber
Journal:  Oncogene       Date:  2018-01-25       Impact factor: 9.867

8.  Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

Authors:  Antonio M Grimaldi; Ester Simeone; Diana Giannarelli; Paolo Muto; Sara Falivene; Valentina Borzillo; Francesca Maria Giugliano; Fabio Sandomenico; Antonella Petrillo; Marcello Curvietto; Assunta Esposito; Miriam Paone; Marco Palla; Giuseppe Palmieri; Corrado Caracò; Gennaro Ciliberto; Nicola Mozzillo; Paolo A Ascierto
Journal:  Oncoimmunology       Date:  2014-05-14       Impact factor: 8.110

9.  Current clinical trials testing the combination of immunotherapy with radiotherapy.

Authors:  Josephine Kang; Sandra Demaria; Silvia Formenti
Journal:  J Immunother Cancer       Date:  2016-09-20       Impact factor: 13.751

10.  Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).

Authors:  A Marabelle; R Andtbacka; K Harrington; I Melero; R Leidner; T de Baere; C Robert; P A Ascierto; J-F Baurain; M Imperiale; S Rahimian; D Tersago; E Klumper; M Hendriks; R Kumar; M Stern; K Öhrling; C Massacesi; I Tchakov; A Tse; J-Y Douillard; J Tabernero; J Haanen; J Brody
Journal:  Ann Oncol       Date:  2018-11-01       Impact factor: 32.976

View more
  24 in total

Review 1.  Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines.

Authors:  Dixita Ishani Viswanath; Hsuan-Chen Liu; David P Huston; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Biomaterials       Date:  2021-11-30       Impact factor: 12.479

Review 2.  Role of Mitochondria in Radiation Responses: Epigenetic, Metabolic, and Signaling Impacts.

Authors:  Dietrich Averbeck; Claire Rodriguez-Lafrasse
Journal:  Int J Mol Sci       Date:  2021-10-13       Impact factor: 5.923

Review 3.  Charting roadmaps towards novel and safe synergistic immunotherapy combinations.

Authors:  Miguel F Sanmamed; Pedro Berraondo; Maria E Rodriguez-Ruiz; Ignacio Melero
Journal:  Nat Cancer       Date:  2022-06-28

4.  Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.

Authors:  Jian Ye; Bradley N Mills; Shuyang S Qin; Jesse Garrett-Larsen; Joseph D Murphy; Taylor P Uccello; Booyeon J Han; Tara G Vrooman; Carl J Johnston; Edith M Lord; Brian A Belt; David C Linehan; Scott A Gerber
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

5.  125 years of BJR and radiological research: reflecting on the anniversary series in celebration of the world's oldest radiology journal.

Authors:  Simon A Jackson; Kevin M Prise
Journal:  Br J Radiol       Date:  2021-01-01       Impact factor: 3.039

Review 6.  Rationale for the Use of Radiation-Activated Mesenchymal Stromal/Stem Cells in Acute Respiratory Distress Syndrome.

Authors:  Isabel Tovar; Rosa Guerrero; Jesús J López-Peñalver; José Expósito; José Mariano Ruiz de Almodóvar
Journal:  Cells       Date:  2020-09-02       Impact factor: 6.600

Review 7.  HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy.

Authors:  Sandeep Arora; Roberta Catania; Amir Borhani; Natally Horvat; Kathryn Fowler; Carla Harmath
Journal:  Abdom Radiol (NY)       Date:  2021-06-30

8.  Impact of proton therapy on antitumor immune response.

Authors:  Céline Mirjolet; Anaïs Nicol; Emeric Limagne; Carole Mura; Corentin Richard; Véronique Morgand; Marc Rousseau; Romain Boidot; François Ghiringhelli; Georges Noel; Hélène Burckel
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

Review 9.  Alerting the immune system to DNA damage: micronuclei as mediators.

Authors:  Kate M MacDonald; Soraya Benguerfi; Shane M Harding
Journal:  Essays Biochem       Date:  2020-10-26       Impact factor: 8.000

10.  Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.

Authors:  Alexander A Pieper; Alexander L Rakhmilevich; Daniel V Spiegelman; Ravi B Patel; Jen Birstler; Won Jong Jin; Peter M Carlson; Deborah H Charych; Jacquelyn A Hank; Amy K Erbe; Willem W Overwijk; Zachary S Morris; Paul M Sondel
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 12.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.